At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 223 enrolled
Drug / intervention
MM-121 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
In Brief
A Phase 2 clinical trial evaluating MM-121 and Paclitaxel for Epithelial Ovarian Cancer and 2 related conditions. Completed, enrolled 223 participants across 10 sites.
Detailed Summary
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsSanofi
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedOct 2011
Primary CompletionSep 2013
Study CompletionJun 2015
TodayJul 2026
First PostedOct 6, 2011
Enrollment StartOct 1, 2011
Primary CompletionSep 1, 2013
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.7 years ago
Interventions
MM-121drug
MM-121 (SAR256212) (IV)
Paclitaxeldrug
Standard dosing Paclitaxel (IV)